Lindsey Shapiro, PhD,  science writer—

Long-term treatment with Isturisa (osilodrostat) led to a sustained normalization in cortisol levels, symptom relief, and improved quality of life for people with Cushing’s disease, according to the full results from the LINC 4 clinical trial and its extension phase. “These data provide further evidence of the durable clinical…

The Phase 3 GRACE trial testing relacorilant in people with Cushing’s syndrome has completed enrollment and data from it is expected next year, according to a recent corporate update from Corcept Therapeutics, its developer. The company plans to submit a new drug application (NDA) to U.S. authorities to market…

People with Cushing’s syndrome, including those with Cushing’s disease, exhibit immune system alterations that could contribute to some symptoms of the disease, a small study suggests. Analyses of immune cells from Cushing’s patients indicated signs of both systemic (whole body) inflammation as well as immunosuppression, which scientists believe might…

The accuracy of late-night testing of cortisol levels in saliva — a common test for diagnosing Cushing’s syndrome — may be lower in real-world clinical practice than in controlled experimental settings, according to a new study from Turkey. The results showed the sensitivity, or true positive rate, of the late-night…

Isturisa (osilodrostat) was found to successfully treat Cushing’s syndrome associated with a hormone-producing tumor in the lungs in a 69-year-old woman with lung cancer, according to a recent case study. The woman simultaneously underwent cancer treatment with Tagrisso (osimertinib), which also was successful. The researchers noted that this case…

Cushing’s syndrome should be considered when osteoporosis, or weak bones, are found in young adults, scientists in China reported. They described treating a 26-year-old woman who came to their clinic with chronic back pain that X-rays identified as due to multiple bone fractures, and who exhibited a number of other…

A severe muscle infection and electrolyte imbalances were among clinical signs leading to a Cushing’s syndrome diagnosis in an 82-year-old woman, according to a recent case report. The patient also showed other cardiovascular risk factors for Cushing’s that aided clinicians in their diagnosis. Infectious complications after a surgery caused the…

Adults and children with endogenous Cushing’s syndrome in Colombia will have access to Metopirone (metyrapone), the first Cushing’s treatment to be approved in the country, HRA Pharma Rare Diseases, which developed and markets the treatment, announced. With this registration, Colombia joins several other countries, including in Europe, the…

Long-term treatment with Recorlev (levoketoconazole) safely leads to sustained reductions in cortisol levels, disease signs and symptoms, and improvements in quality of life in adults with endogenous Cushing’s syndrome, according to nearly two years of data from the Phase 3 SONICS trial. Treatment benefits were generally maintained or deepened…

Isturisa (osilodrostat) led to sustained reductions in cortisol levels in people with Cushing’s disease over nearly seven years of treatment in an extension phase of the Phase 2 LINC-2 trial. Cardiovascular symptoms were also well controlled throughout the study and no new safety signals were detected. “These data…